HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

NCT02143830 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Fanconi Anemia
Severe Marrow Failure
Myelodysplastic Syndrome (MDS)
Acute Myelogenous Leukemia (AML)

Interventions

DRUG: Busulfan
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: rabbit ATG
DRUG: G-CSF
BIOLOGICAL: Peripheral blood stem cell

Sponsor

Children's Hospital Medical Center, Cincinnati

Collaborators

[object Object]
[object Object]